Loading stock dossier…
Bafna Pharmaceuticals Limited is a micro-cap Healthcare stock trading at a price-to-earnings of 31.8, placing it in the 53rd percentile of Healthcare sector (lower is cheaper). The composite smart-money score (insider + FII/DII flow + block deals + mutual-fund accumulation) is currently in the "NEUTRAL" bucket.
Up to 10 years of daily closes, with vertical hairlines marking the dates of earnings announcements (accent), ownership inflections (red), and dividend ex-dates (faint). Hover any hairline for the event label.
Hover the chart for a date+price readout; click any vertical hairline to pin its event label.
Two views of how the market is valuing this stock. Implied growth reverse-engineers the annual growth rate baked into the current P/E. Snowflake places the stock on five orthogonal axes from MintByte's in-house model.
| 2023 | — | |||
| 2022 | — | — | — | — |
| 2021 | — | — | — | — |
| 2020 | — | — | — | — |
One rupee invested at the start, plotted on a log scale, with closes back-adjusted for every stock split and bonus issue across the window. The headline reads the cumulative outcome; the CAGR badge annualises it.
Every historical drawdown of 12% or more in the available 10 years of EOD data. The left bar shows depth; the right bar shows months until the price made a new all-time high.
Two views of recent event-driven price action: the earnings-reaction grid shows how the market traded the day after each of the last 8 quarterly results, and the insider heat strip shows weekly net insider buying/selling over the last 90 days.
| Date | Insider | Category | Type | Qty |
|---|
Equity prices and ratios are computed from NSE / BSE end-of-day data. No content on this page constitutes a buy / sell / hold recommendation. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
Implied growth and ROE are derived from a simplified Gordon-growth model: g = (PE × r − 1) / (PE + 1) with cost-of-equity r = 12% (a standard India-equity assumption). This is a thought-experiment, not a forecast. Not investment advice.
Each axis is a 0–5 score from MintByte's snowflake compute. Value = valuation cheapness · Future = growth potential · Past = track record · Health = balance-sheet strength · Dividends = payout & yield.
No signal at present — see methodology for the criteria.
No signal at present — see methodology for the criteria.
SWOT items are auto-derived from quantitative factor scores, Smart Money sentiment, and shareholding snapshot. They are not investment advice.
Each factor is computed monthly from the in-house model and bucketed into quintiles across the active equity universe. Q1 = top quintile on that factor (favourable position) · Q5 = bottom quintile.
T+1 = close one trading session after the result announcement (or next trading day).
| Value |
|---|
| 29 Mar 2025 | SRJR LIFESCIENCES LLP | Promoters | SELL | 3,14,530 | ₹2Cr |
| 20 Sept 2022 | SRJR LIFESCIENCES LLP | Promoters | SELL | 8,897 | ₹9L |
| 15 Sept 2022 | SRJR LIFESCIENCES LLP | Promoters | SELL | 9,883 | ₹11L |
| 16 Jun 2022 | SRJR LIFESCIENCES LLP | Promoters | SELL | 27,218 | ₹33L |
| 8 Jun 2022 | SRJR LIFESCIENCES LLP | Promoters | SELL | 13,135 | ₹17L |
| 6 Jun 2022 | SRJR LIFESCIENCES LLP | Promoters | SELL | 11,123 | ₹14L |
| 3 Jun 2022 | SRJR LIFESCIENCES LLP | Promoters | SELL | 14,756 | ₹18L |
| 2 Sept 2021 | AMRIBAI BAFNA | Promoters | PLEDGE INVOKE | 50,000 | ₹0 |
| 31 May 2021 | Chetna Bafna | Promoters | SELL | 2,13,280 | ₹0 |
| 24 Dec 2020 | SRJR Lifesciences LLP | Promoters | BUY | 2,12,90,701 | ₹55Cr |